USE OF A NEUTROPHIL ELASTASE INHIBITOR IN LUNG DISEASE
The invention relates to methods for treating chronic lung disease, in particular, alpha-1 antitrypsin deficiency or emphysema resulting from alpha-1 antitrypsin deficiency, with a neutrophil elastase inhibitor. The invention further relates to pharmaceutical compositions comprising a neutrophil elastase inhibitor.
1 . A method of treating chronic lung disease, comprising administering a therapeutically effective amount of (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile or a pharmaceutically acceptable salt, polymorph, solvate, or solvates of the salts thereof to a patient in need of treatment, wherein the therapeutically effective amount comprises a dosage of 1 mg, 2 mg, 5 mg, 10 mg, 20 mg or 40 mg once a day, and wherein the chronic lung disease is selected from the group consisting of alpha-1 antitrypsin deficiency or emphysema resulting from alpha-1 antitrypsin deficiency.
2 . The method of claim 1 , wherein the chronic lung disease is alpha-1 antitrypsin deficiency.
3 . The method of claim 1 , wherein the chronic lung disease is emphysema resulting from alpha-1 antitrypsin deficiency.
4 . The method of claim 1 , further comprising administering one or more additional therapies.
5 . The method of claim 4 , wherein the additional therapy is augmentation therapy with human alpha-1 antitrypsin.
6 . The method of claim 4 , wherein the additional therapy is treatment with a therapeutic agent when administered to a patient by itself treats or ameliorates alpha-1 antitrypsin deficiency or emphysema resulting from alpha-1 antitrypsin deficiency.
7 . The method of claim 6 , wherein the therapeutic agent is an alpha-1 antitrypsin modulator, gene therapy, RNA-based therapy, a leukocyte elastase inhibitor or recombinant AAT.
8 . A pharmaceutical composition for the treatment of alpha-1 antitrypsin deficiency or emphysema resulting from alpha-1 antitrypsin deficiency comprising (4S)-4-[4-cyano-2-(methyl sulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile or a pharmaceutically acceptable salt, polymorph, solvate, or solvates of the salts thereof and a pharmaceutically acceptable carrier.
9 . The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is formulated as a tablet.
10 . The pharmaceutical composition of claim 9 , wherein the tablet comprises one or more diluents, disintegrants, surfactants or lubricants.
11 . The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition comprises 1 mg, 2 mg, 5 mg, 10 mg, 20 mg or 40 mg of (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile or a pharmaceutically acceptable salt, polymorph, solvate, or solvates of the salts thereof.
12 . A method of treating alpha-1 antitrypsin deficiency or emphysema resulting from alpha-1 antitrypsin deficiency in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition according to claim 8 .
13 . The method of claim 12 , wherein the pharmaceutical composition comprises 1 mg, 2 mg, 5 mg, 10 mg, 20 mg or 40 mg of (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile or a pharmaceutically acceptable salt, polymorph, solvate, or solvates of the salts thereof.
14 - 20 . (canceled)